Steris plc stock (IE00BFY8C754): NYSE price hovers around 210 USD as investors look through fiscal 2026 figures

Steris plc shares are trading close to 210 USD on the NYSE in early June while the U.S.-listed medical sterilization specialist continues to be digested by investors after reporting its latest fiscal 2026 results, with the stock valued at a mid?20s earnings multiple and offering a modest dividend yield.

Steris plc shares remained relatively stable on the New York Stock Exchange in early June, with the U.S.-listed healthcare sterilization and infection prevention provider changing hands at roughly 210 USD as investors in the United States continue to process the group’s recently reported fiscal 2026 results, according to an overview from ad-hoc-news.de based on U.S. trading data as of 06/03/2026.

The stock traded around USD 210.14 on 06/03/2026 on the NYSE, implying a market capitalization of approximately USD 20.5 billion and corresponding to a price-to-earnings ratio of about 26.5 and a dividend yield near 1.2 percent, according to Nasdaq-quoted metrics summarized by Robinhood as of 06/03/2026.Robinhood as of 06/03/2026

As of: 06/04/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Steris plc
• Sector/industry: Medical equipment and infection prevention solutions
• Headquarters/country: Dublin, Ireland
• Core markets: United States, Europe, and other international healthcare markets
• Key revenue drivers: Sterilization equipment, consumables, and infection prevention services for hospitals, pharmaceutical and life-sciences customers
• Home exchange/listing venue: New York Stock Exchange (STE)
• Trading currency: USD

Steris plc: core business model

Steris focuses on providing sterilization technologies, surgical equipment, and related infection prevention services to healthcare providers and life-sciences companies, generating most of its revenue from equipment sales, recurring consumables, and long-term service contracts that support hospitals and pharmaceutical manufacturers.

Industry trends and competitive position

The global market for sterilization and disinfection products continues to be supported by structural growth in procedure volumes, aging populations, and tightening infection-control standards in hospitals and ambulatory surgery centers, which together underpin demand for solutions such as those offered by Steris, according to sector analyses from firms like S&P Global and Statista published over the past few years focusing on the broader medical devices and infection control industry.

Within this environment, Steris competes with other large medical technology and sterilization players in the United States and internationally, typically emphasizing integrated offerings that bundle capital equipment with consumables and services, a model that is designed to strengthen long-term customer relationships and provide recurring revenue streams alongside one-time equipment installations.

Conclusion

Steris plc is currently valued by U.S. investors at around USD 210 per share on the NYSE, translating into a mid-20s earnings multiple and a modest cash yield after the release of its latest fiscal 2026 numbers.

Set against broader growth in the medical sterilization and infection prevention market, the company’s business model built on equipment, consumables, and services continues to be a focal point in discussions about how the stock may react to future operating performance and capital allocation decisions.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.